NASDAQ:BLPHBellerophon Therapeutics Stock Price, Forecast & News

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLPH shares have increased by 136.4% and is now trading at $14.87. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellerophon Therapeutics.

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Bellerophon Therapeutics.

Bellerophon Therapeutics Inc (NASDAQ:BLPH) issued its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.02) by $0.13. View Bellerophon Therapeutics' earnings history.

Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

3 equities research analysts have issued 1 year price targets for Bellerophon Therapeutics' stock. Their forecasts range from $30.00 to $35.00. On average, they expect Bellerophon Therapeutics' share price to reach $31.67 in the next twelve months. This suggests a possible upside of 113.0% from the stock's current price. View analysts' price targets for Bellerophon Therapeutics.

Headlines about BLPH stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutBellerophon Therapeutics.

Bellerophon Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 87,600 shares, a decrease of 21.1% from the April 30th total of 111,000 shares. Based on an average daily trading volume, of 973,000 shares, the short-interest ratio is currently 0.1 days. Currently, 4.7% of the company's stock are sold short. View Bellerophon Therapeutics' Current Options Chain.

Some companies that are related to Bellerophon Therapeutics include Spectrum Pharmaceuticals (SPPI), Organogenesis (ORGO), Selecta Biosciences (SELB), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Avadel Pharmaceuticals (AVDL), Ovid Therapeutics (OVID), MannKind (MNKD), Rigel Pharmaceuticals (RIGL), Menlo Therapeutics (MNLO), Verastem (VSTM), Concert Pharmaceuticals (CNCE), Avid Bioservices (CDMO), Lannett (LCI) and Neptune Wellness Solutions (NEPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Vaxart (VXRT), Novavax (NVAX), VBI Vaccines (VBIV), Opko Health (OPK), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Clovis Oncology (CLVS).

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include New Mountain Vantage Advisers L.L.C. (1.63%), Telemetry Investments L.L.C. (0.82%), Credit Agricole S A (0.05%) and Morgan Stanley (0.04%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang. View institutional ownership trends for Bellerophon Therapeutics.

BLPH stock was sold by a variety of institutional investors in the last quarter, including New Mountain Vantage Advisers L.L.C., and Telemetry Investments L.L.C.. View insider buying and selling activity for Bellerophon Therapeutics.

BLPH stock was purchased by a variety of institutional investors in the last quarter, including Credit Agricole S A, and Morgan Stanley. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin, and Theodore T Wang. View insider buying and selling activity for Bellerophon Therapeutics.

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLPH stock can currently be purchased for approximately $14.87.

Bellerophon Therapeutics has a market capitalization of $91.18 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]